GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

Completed · Phase 1 · Has a placebo group

Conditions studied: Obesity

In brief

To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.

Key facts

Study ID

NCT04779697

Run by

Yale University

People needed

96

Starts

2021-02-01

Expected to finish

2024-11-19

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BMI ranging from 30-49.9 kg/m2
• No significant medical problems, including diabetes
• No history of HgbA1c <6.5%
• English speaking and able to read English and complete study evaluations
• Able to provide informed written and verbal consent

You may not qualify if…

• Any significant current medical conditions, including neurological, renal, thyroid, cardiovascular, liver, endocrine or immune conditions, including diagnosis of T2DM or T1DM by American Diabetes Association (ADA) criteria
• Meet current or past DSM-IVR criteria for alcohol dependence or any substance use disorders, including nicotine, or psychiatric disorders, including eating disorders, or use of any psychiatric medications, including anxiolytics, antidepressants, naltrexone or antabuse, anti-smoking medications
• Current active participation in a weight loss program or weight loss of >10% of total body weight during the prior 6 months
• Taking any other anti-obesity medication
• History of pancreatitis, medullary thyroid cancer, or MEN syndrome, or (6) women who are pregnant or lactating, or peri/postmenopausal

Where it is running

• The Yale Stress Center: Yale University — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.